Brazil Medical Cannabis Market Size, Share, Trends and Forecast 2026-2034

The Brazil medical cannabis market was valued at USD 856.53 Million in 2025 and is forecast to reach USD 1,546.74 Million by 2034, growing at a CAGR of 6.79% during 2026-2034. This growth is driven by expanding therapeutic applications, advancements in cultivation technologies, and increasing digital integration that collectively improve patient access and treatment efficiency. Regulatory support and clinical acceptance are further enabling market expansion, reflecting a mature and steadily growing industry.

Study Assumption Years

• Base Year: 2025
• Historical Year/Period: 2020-2025
• Forecast Year/Period: 2026-2034

Brazil Medical Cannabis Market Key Takeaways

• The market size reached USD 856.53 Million in 2025.
• The market is expected to grow at a CAGR of 6.79% from 2026 to 2034.
• The forecast period of the study is 2026-2034.
• Increasing acceptance among clinicians for treating chronic pain, neurological disorders, and palliative care is driving therapeutic use.
• Technological advancements in cultivation such as controlled environment agriculture and precision irrigation are enhancing product quality and scalability.
• Digital technologies like telemedicine and electronic prescriptions are improving patient access and treatment monitoring.
• Regulatory adjustments including authorization for industrial hemp cultivation are facilitating market growth.

Sample Request Link: https://www.imarcgroup.com/brazil-medical-cannabis-market/requestsample

Market Growth Factors

The Brazilian medical cannabis market is expanding rapidly due to the growing recognition of the therapeutic potential of cannabis-based products. Increasing clinical acceptance of cannabinoids as valid treatments for chronic pain, neurological disorders, and palliative care is fostering the development of innovative product formulations including oils, capsules, and transdermal delivery systems. Continuous clinical trials and research studies are unveiling new therapeutic applications, enabling evidence-based adoption by healthcare practitioners. Regulatory systems are adapting gradually to enhance patient access while ensuring safety, leading to a broader and more diverse patient base.

Technological advancements in cultivation processes are revolutionizing the market by improving the quality and scalability of cannabis products. Techniques such as controlled environment agriculture, precision irrigation, and maximized light exposure are increasing cannabinoid concentrations and ensuring batch consistency. These scientific cultivation methods enable the development of strains optimized for specific therapeutic needs and promote sustainable resource consumption. Supportive regulations for local cultivation are prompting investments in advanced facilities and secure supply chains, strengthening the overall production infrastructure and facilitating healthcare integration.

The integration of digital healthcare technologies is transforming patient access and participation in the medical cannabis market. Tools such as telemedicine platforms, electronic prescriptions, and patient registries allow healthcare professionals to track therapy compliance and adjust treatments accurately, especially for patients in remote areas. Mobile applications provide educational resources, symptom management guidance, and product advice, increasing patient knowledge and confidence. These digital solutions enhance accessibility, individual care, and treatment safety, contributing significantly to market expansion by improving patient participation and enabling scalable distribution channels.

Market Segmentation

Species Insights:

• Indica: The report covers the indica species, highlighting its role within Brazil's medical cannabis market.
• Sativa: Sativa species are analyzed for their application and market presence.
• Hybrid: The hybrid species segment is included, focusing on combinations of indica and sativa strains.

Derivatives Insights:

• Cannabidiol (CBD): CBD derivatives are noted for their therapeutic use and market share.
• Tetrahydrocannabinol (THC): THC derivatives are included, reflecting their role in medical applications.
• Others: Other cannabis derivatives are also accounted for in market analysis.

Application Insights:

• Cancer: Medical cannabis is applied for cancer treatment within the Brazilian market.
• Arthritis: Usage for arthritis care is detailed.
• Migraine: Treatment of migraines with cannabis products is examined.
• Epilepsy: Medical cannabis applications for epilepsy are reviewed.
• Others: Additional medical applications are considered.

Route of Administration Insights:

• Oral Solutions and Capsules: These are popular forms of cannabis delivery highlighted in the report.
• Vaporizers: Vaporizing as a route of administration is analyzed.
• Topicals: Use of topical products is covered.
• Others: Other administration routes are included.

End Use Insights:

• Pharmaceutical Industry: The pharmaceutical sector's usage of medical cannabis is explored.
• Research and Development Centres: These centers' roles in cannabis research and development are discussed.
• Others: Other end-use categories are presented.

Regional Insights

The report provides a comprehensive regional breakdown including Southeast, South, Northeast, North, and Central-West regions of Brazil. No specific statistics such as market shares or regional CAGRs are provided outright in the source. Thus, no region is singled out as dominant based on data explicitly given.

Recent Developments & News

In January 2025, MediPharm Labs Corp entered a significant commercial agreement with Laboratório Teuto, a leading Brazilian pharmaceutical manufacturer. ANVISA granted Teuto sanitary authorizations for two pharmaceutical-grade medical cannabis products produced by MediPharm, with approvals issued on December 30, 2024. This partnership leverages Teuto's extensive distribution network to strengthen its position in pharmaceutical cannabis across Brazil. In January 2024, Avicanna and Ease Labs Pharma secured ANVISA approval for Brazil's first THC-containing pharmaceutical preparation, a GMP-certified product containing 2.5% CBD and up to 0.2% THC, set to be available in pharmacies by March 2024.

Key Players

• MediPharm Labs Corp
• Laboratório Teuto
• Avicanna
• Ease Labs Pharma

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302